Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (PubMed, Rinsho Ketsueki) - Aug 31, 2026 - "Ponatinib, a third-generation TKI, has shown promising results, especially in high-risk patients and those with the T315I mutation, although clinical evidence is limited due to small study populations. Although TKI administration after HSCT has generally demonstrated potential benefits, prospective trials are needed to provide robust evidence."
Journal • Review • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation
|